The idea of a new therapy which enhances GILZ expression, and/or targets the same molecular pathways as GILZ, is a very attractive one with the potential to provide a critically-needed replacement for GC therapy in SLE. Here, TSC22D3 is linked to systemic lupus erythematosus.